Shark Tank Original Member Kevin Harrington Joins Forces with UVLrx Therapeutics, Inc.

UVLrx
Therapeutics, Inc. announces its partnership with Kevin Harrington,
investor, inventor, and one of the original “sharks” on the hit ABC
television series, “Shark Tank”. Harrington will oversee the marketing
and growth of the company’s light therapy devices, which deliver
multiple visible light wavelengths intravenously to treat a variety of
conditions through the bloodstream.

“I’ve been introduced to thousands of products from around the world and
I’ve never had the opportunity to represent a product, let alone a
medical device, that could change medical history as we know it,” says
Harrington. “I’m thrilled to be on this team and I look forward to the
positive impact UVLrx Therapeutics, will have on global healthcare.”

Over the past 30 years, Harrington’s products and businesses have
exceeded $5 Billion USD in sales across 100 countries. He was also the
pioneer of As Seen On TV.

“Kevin has a reputation for identifying viable, high-impact businesses
and growing them into industry leaders,” says UVLrx Therapeutics founder
Michael Harter. “His contributions as an advisor and investor will allow
us to expand the distribution of our light therapy treatment system
around the world, which means we’ll reach more people and animals in
need.”

UVLrx treatment systems emit three wavelengths of light in a unique
parallel combination. RED light (630nm), UVA light (365nm), and GREEN
light (530nm) are seamlessly integrated into an IV catheter illuminating
the passing blood supply. Using the company’s patented Dry Light
Adapter™ integration with an IV, the device treats blood intravenously.

Literature has shown these three wavelengths may have potential benefits
with:

Learn
more about IV light therapy for humans in these videos.

Learn
more about IV light therapy for animals in these videos.

About UVLrx Therapeutics, Inc.

Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to
evidence-based medicine in the field of light therapy and offers the
first known intravenous, concurrent delivery of Ultraviolet-A (UVA), RED
and GREEN light wavelengths. In addition to two Nobel Prizes and
NASA-backed research, hundreds of international clinical trials have
verified the health benefits of UV and other wavelengths of light
utilized in the UVLrx™ Treatment System.

For more information, please email info@uvlrx.com
or call 844-885-7979.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180710006079/en/

Leave a Comment